Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2017
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic LeukemiaMatthew S Simon, Lars F Westblade, Alexis Dziedziech, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Leukemia Research|May 4, 2007
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz, John M Bennett, Morton Coleman, et al.
Cancer|July 29, 2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaRichard R Furman, Peter Martin, Jia Ruan, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemiaDianne Pulte, Richard R Furman, M Johan Broekman, et al.
Blood|July 2, 2008
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignanciesLuca Paoluzzi, Mithat Gonen, Govind Bhagat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinibZibo Song, Pin Lu, Richard R Furman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaMelissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Blood|March 31, 2021
Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX modelsAndrea Iannello, Nicoletta Vitale, Silvia Coma, et al.
Blood Advances|March 19, 2024
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinibJavid J Moslehi, Richard R Furman, Constantine S Tam, et al.
Pageof 14